相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines
Joseph J. Palamar et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2020)
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
Malin Uthaug et al.
PSYCHOPHARMACOLOGY (2020)
Psychedelic Psychiatry's Brave New World
David Nutt et al.
CELL (2020)
Anxiety-like behavior induced by salicylate depends on age and can be prevented by a single dose of 5-MeO-DMT
Jessica Winne et al.
EXPERIMENTAL NEUROLOGY (2020)
Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics
James Daniel Sexton et al.
FRONTIERS IN PSYCHIATRY (2020)
Chronic pain and psychedelics: a review and proposed mechanism of action
Joel P. Castellanos et al.
REGIONAL ANESTHESIA AND PAIN MEDICINE (2020)
Historic psychedelic drug trials and the treatment of anxiety disorders
Neil M. Weston et al.
DEPRESSION AND ANXIETY (2020)
2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report
David D. Gummin et al.
CLINICAL TOXICOLOGY (2020)
A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT) in a naturalistic setting
M. A. L. I. N. V. Uthaug et al.
JOURNAL OF PSYCHEDELIC STUDIES (2020)
Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects
Nathan D. Sepeda et al.
JOURNAL OF PSYCHEDELIC STUDIES (2020)
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
Rafael L. Lancelotta et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2020)
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Friederike Holze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017
Joseph J. Palamar et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2019)
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Alan K. Davis et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2019)
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
M. V. Uthaug et al.
PSYCHOPHARMACOLOGY (2019)
Neural correlates of the DMT experience assessed with multivariate EEG
Christopher Timmermann et al.
SCIENTIFIC REPORTS (2019)
Psychiatry & the psychedelic drugs. Past, present & future
James J. H. Rucker et al.
NEUROPHARMACOLOGY (2018)
The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
Maurizio S. Riga et al.
NEUROPHARMACOLOGY (2018)
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Tehseen Noorani et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Alan K. Davis et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson et al.
NEUROPHARMACOLOGY (2018)
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Michael P. Bogenschutz et al.
FRONTIERS IN PHARMACOLOGY (2018)
A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus
Rafael Vitor Lima da Cruz et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
Joseph Barsuglia et al.
FRONTIERS IN PSYCHOLOGY (2018)
Psychedelics, Meditation, and Self-Consciousness
Raphael Milliere et al.
FRONTIERS IN PSYCHOLOGY (2018)
The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
Clinton E. Canal et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Vanja Dakic et al.
SCIENTIFIC REPORTS (2017)
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
Thomas Pokorny et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors
Maurizio S. Riga et al.
NEUROPHARMACOLOGY (2016)
Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms
Xi-Ling Jiang et al.
PHARMACOLOGICAL REPORTS (2016)
Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine
Adam L. Halberstadt
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2016)
Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice
Xi-Ling Jiang et al.
ACTA PHARMACEUTICA SINICA B (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
Examining the Factor Structure of the 39-Item and 15-Item Versions of the Five Facet Mindfulness Questionnaire Before and After Mindfulness-Based Cognitive Therapy for People With Recurrent Depression
Jenny Gu et al.
PSYCHOLOGICAL ASSESSMENT (2016)
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors
Xi-Ling Jiang et al.
NEUROPHARMACOLOGY (2015)
The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs
Maurizio S. Riga et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells
Attila Szabo et al.
PLOS ONE (2014)
Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes
Bruce E. Blough et al.
PSYCHOPHARMACOLOGY (2014)
Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status
Xi-Ling Jiang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Emerging psychoactive substance use among regular ecstasy users in Australia
Raimondo Bruno et al.
DRUG AND ALCOHOL DEPENDENCE (2012)
A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010
Steven A. Barker et al.
DRUG TESTING AND ANALYSIS (2012)
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor
Adam L. Halberstadt et al.
PSYCHOPHARMACOLOGY (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice
Adam L. Halberstadt et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: Implications for schizophrenia
Maarten van den Buuse et al.
NEUROPHARMACOLOGY (2011)
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Adam L. Halberstadt et al.
NEUROPHARMACOLOGY (2011)
Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice
J. C. Winter et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice
Hong-Wu Shen et al.
DRUG METABOLISM AND DISPOSITION (2011)
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics
Hong-Wu Shen et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Psychedelic 5-Methoxy-N,N-Dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions
Hong-Wu Shen et al.
CURRENT DRUG METABOLISM (2010)
Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
Cullen L. Schmid et al.
JOURNAL OF NEUROSCIENCE (2010)
Psychedelics and the Human Receptorome
Thomas S. Ray
PLOS ONE (2010)
Intrahippocampal LSD accelerates learning and desensitizes the 5-HT2A receptor in the rabbit, Romano et al.
Anthony G. Romano et al.
PSYCHOPHARMACOLOGY (2010)
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study
R. L. Carhart-Harris et al.
JOURNAL OF SUBSTANCE USE (2010)
Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception
J. V. Wallach
MEDICAL HYPOTHESES (2009)
5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition
Vikas Duvvuri et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2009)
Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine: application to pharmacokinetic study
Hong-Wu Shen et al.
BIOANALYSIS (2009)
Human hallucinogen research: guidelines for safety
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
Adam L. Halberstadt et al.
PSYCHOPHARMACOLOGY (2008)
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Fumiko Nagai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
Javier Gonzalez-Maeso et al.
NEURON (2007)
Functional selectivity and classical concepts of quantitative pharmacology
Jonathan D. Urban et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats
Kirsten Krebs-Thomson et al.
PSYCHOPHARMACOLOGY (2006)
5-Hydroxytryptamine receptors in the human cardiovascular system
Alberto J. Kaumann et al.
PHARMACOLOGY & THERAPEUTICS (2006)
A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation
J Sklerov et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2005)
The short-form version of the Depression Anxiety Stress Scales (DASS-21): Construct validity and normative data in a large non-clinical sample
JD Henry et al.
BRITISH JOURNAL OF CLINICAL PSYCHOLOGY (2005)
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study
F Hasler et al.
PSYCHOPHARMACOLOGY (2004)
Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys
WE Fantegrossi et al.
BEHAVIOURAL PHARMACOLOGY (2004)
The molecular acrobatics of arrestin activation
VV Gurevich et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Spinal 5-HT2A receptors regulate cutaneous sympathetic vasomotor outflow in rabbits and rats; relevance for cutaneous vasoconstriction elicited by MDMA (3,4-methylenedioxymethamphetamine, Ecstasy) and its reversal by clozapine
Y Ootsuka et al.
BRAIN RESEARCH (2004)
Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances
DE Brush et al.
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY (2004)
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase
AM Yu et al.
PHARMACOGENETICS (2003)
Serotonin 5-hydroxytryptamine(2A) receptor-coupled phospholipase C and phospholipase A(2) signaling pathways have different receptor reserves
DM Kurrasch-Orbaugh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Involvement of 5-hydroxytryptamine neuronal system in Δ9-tetrahydrocannabinol-induced impairment of spatial memory
N Egashira et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Pharmepena-psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine
J Ott
JOURNAL OF PSYCHOACTIVE DRUGS (2001)
Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection:: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method
SA Barker et al.
JOURNAL OF CHROMATOGRAPHY B (2001)
The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches?
BL Roth et al.
NEUROSCIENTIST (2000)
The paradox of 5-methoxy-N,N-dimethyltryptamine: An indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors
JC Winter et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2000)
分享论文
